Should You Sell AST SpaceMobile to Buy SpaceX at IPO?

SpaceX’s expected $2 trillion IPO on June 12 is prompting investors to raise cash, with the article arguing AST SpaceMobile should not be sold to buy SpaceX. AST is up more than 30% this year, while SpaceX is estimated to debut at 107x 2025 sales and AST at 288x last year's sales; analysts see AST revenue reaching $1.9 billion by 2028 versus SpaceX at $41.1 billion. The piece favors AST on relative valuation and growth, but notes AST remains unprofitable and heavily reliant on SpaceX rockets for launches.

Analysis

The real second-order trade is not “AST vs. SpaceX,” but whether near-term liquidity demand around the SpaceX float temporarily pressures the rest of the small-cap satellite/space complex while re-rating the addressable market for direct-to-device connectivity. That creates a window where AST can de-link from the headline and trade on its own execution risk: if launches slip or customer conversion stalls, the stock can compress hard despite long-duration optionality. Conversely, if the IPO validates the category, AST benefits from a higher private-market comp set even if it is not the same business model.

The key market misconception is that cheaper on forward sales automatically means better risk/reward. AST’s multiple can look optically lower because the revenue ramp is earlier, but the equity is effectively a series of binary launch, insurance, and customer-activation milestones over the next 6–18 months. A small miss on deployment cadence or capex funding can force another equity raise, which would matter more than any long-dated 2028 estimate.

For carriers T, TMUS, and VZ, the important implication is bargaining power: a credible second supplier of direct-to-device coverage reduces dependence on a single ecosystem and should improve wholesale pricing discipline over time. But in the next few quarters, carriers are likely to keep AST in pilot/optionality mode until coverage is real, meaning the monetization curve is slower than the narrative suggests. That argues for trading AST as a catalyst stock, not a compounder you want to own through a financing window.

The contrarian view is that SpaceX’s IPO may actually be the better sentiment event for AST than for SpaceX itself, because it forces public investors to benchmark the whole category and highlights AST’s pure-play exposure. The danger is that speculative capital chases the new listing and funds it by trimming the highest beta incumbent, creating a temporary but tradable underperformance in AST over the next 1-4 weeks before fundamentals reassert. The setup is less about choosing the winner and more about timing liquidity and dilution risk correctly.

Key Decisions for Investors

• Reduce ASTS into strength over the next 1-2 weeks; keep only a residual starter position for launch/contract upside. Risk/reward: favorable if you avoid a 15-25% de-rating from any IPO-driven rotation or financing headline.
• Pair trade: long T or VZ vs short ASTS for 1-3 months. Thesis: carriers monetize direct-to-device optionality with less execution risk, while ASTS carries binary launch/funding risk; target 10-15% relative outperformance if sentiment fades.
• Avoid chasing SpaceX at debut; wait for post-IPO lockup/price discovery. If you want category exposure, buy on a 10-20% pullback after the first 2-4 weeks of trading when forced selling and narrative compression usually fade.
• For ASTS holders, hedge event risk with short-dated call spreads or put spreads around launch/financing windows rather than outright selling if you need upside participation. This preserves convexity while capping gap-down risk from schedule slippage.